Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASN 100 (Primary)
  • Indications Pneumonia; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Arsanis
  • Most Recent Events

    • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
    • 09 Nov 2018 According to an Arsanis Biosciences media release, follow-up visits for all 154 patients who were enrolled in this study were completed and the trial database was locked during the third quarter of 2018.
    • 28 Jun 2018 Arsanis Biosciences has discontinued this trial following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC). The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion and recommended that trial enrollment be discontinued. The company intends to conduct follow-up visits on all patients dosed with ASN100, according to an Arsanis Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top